NDC product
Lotensin HCT
NDC 30698-452 · Validus Pharmaceuticals LLC
Key facts
| Product NDC | 30698-452 |
|---|---|
| Proprietary name | Lotensin HCT |
| Nonproprietary name | benazepril hydrochloride and hydrochlorothiazide |
| Substances | BENAZEPRIL HYDROCHLORIDE, HYDROCHLOROTHIAZIDE |
| Dosage form | TABLET |
| Route | ORAL |
| Labeler | Validus Pharmaceuticals LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA020033 |
| Pharmacologic classes | Angiotensin Converting Enzyme Inhibitor [EPC], Angiotensin-converting Enzyme Inhibitors [MoA], Decreased Blood Pressure [PE], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS] |
| Marketing start | May 30, 1992 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: